News

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Novo Nordisk's new CEO sounds the alarm on peptides.

Novo Nordisk's new CEO sounds the alarm on peptides.

Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.

Eli Lilly is worth 5.5x Novo Nordisk but earns nowhere near 5.5x more. Here's how the obesity pill war, a 13x vs. 32x valuation gap, and the dividend stack up, and which one I'd buy.

Novo Nordisk A/S (NYSE:NVO) has delivered encouraging late-stage data for Wegovy in younger children, with its STEP Young trial showing that 40.4% of children aged 6 to under 12 were no longer classified as having obesity after 68 weeks of semaglutide treatment, compared with none in the placebo group. The trial met its primary endpoint, […]

A pediatric obesity success collided with another cardiovascular retreat, leaving Novo's concentration problem unresolved.

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Yahoo Finance Executive Editor Brian Sozzi chats with Novo Nordisk CEO Mike Doustdar about the true timeline for how GLP-1s will impact the food and airline industries, and what the future of weight loss and preventative health looks like over the next decade.

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and

Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched. With fresh questions around obesity drug competition, patent risk and a changing leadership team, investors are weighing whether that discount is a warning sign or an opportunity. The share price has declined 51.9% over the past three years, which puts a clear spotlight on whether the current level already reflects the main concerns around...

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

Germany is the first EU pill market, but pen-equivalent pricing means convenience--not discounting--must win adoption.

European equities traded in the US as American depositary receipts were marginally higher late Frida

You might regret ignoring these companies at current levels.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively tr

Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.

PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

Novo Nordisk A/S (NYSE:NVO) has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available. Germany is the EU’s largest pharmaceutical market, so the launch is an important step for Novo as it works to strengthen its position in the […]

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

European equities traded in the US as American depositary receipts were trending higher late Wednesd

Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail...

Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.

The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide

Novo Nordisk (CPSE:NOVO B) is back in focus after launching its Wegovy pill in Germany, the first EU market to offer the oral weight loss treatment, putting its GLP-1 obesity ambitions under closer investor scrutiny. The stock has been under pressure despite Novo Nordisk’s obesity pipeline progress, with a 30 day share price return of 4.16%, a year to date share price return decline of 11.05%, and a 1 year total shareholder return down 14.14%. This suggests momentum has faded recently after...

Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.

GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.

Long CEO tenures and a preference for insiders have left half of boardrooms in the Nordic and Benelux countries doubting their CEO's skills match what the company needs to deliver.